Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2014
Business Overview: NanoViricides is a development-stage biopharmaceutical company focused on creating "nanoviricides," a nanomedicine platform designed to attack viral particles directly. The company holds an exclusive perpetual license to the underlying technology from TheraCour Pharma, Inc. As of the reporting date, the company had no commercialized products and generated no revenue. Key milestones during the period included the completion of a cGMP-capable manufacturing facility in Shelton, CT, and the uplisting of common stock to the NYSE MKT in September 2013.
Key Financial Metrics
| Metric | Year Ended June 30, 2014 | Year Ended June 30, 2013 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(8,875,667) | $(6,207,207) |
| Operating Expenses | $8,667,372 | $6,590,379 |
| Research & Development | $5,131,523 | $4,292,909 |
| General & Administrative | $3,535,849 | $2,297,470 |
| Cash and Cash Equivalents (End of Period) | $36,696,892 | $13,923,245 |
| Stockholders' Equity | $28,604,985 | $8,009,654 |
| Accumulated Deficit | $(52,406,258) | $(38,299,783) |
Note: The filing text contains conflicting data in the "Selected Financial Data" table versus the "Management's Discussion and Analysis" section regarding cash balances. The MD&A section explicitly states cash of $36.7M as of June 30, 2014, which aligns with the narrative of recent financings. The table lists $13.9M for 2014 but $36.7M for 2013, which appears to be a typographical error in the source text given the context of the $20M financing in Jan 2014. The summary above utilizes the $36.7M figure as the accurate end-of-period cash balance based on the MD&A narrative.
Material Changes vs. Prior Period
- Significant Financing: The company raised approximately $20 million in a registered direct offering in January 2014 and approximately $10 million in September 2013. This resulted in a substantial increase in cash reserves from ~$13.9M in the prior year to ~$36.7M at period end.
- Increased Operating Loss: Net loss increased by approximately $2.67 million (43%) compared to the prior year, driven by higher R&D and G&A expenses as the company advanced its drug pipeline and expanded corporate governance.
- Facility Completion: The company completed the construction of a cGMP-capable manufacturing facility in June 2014, a critical milestone for advancing drug candidates to clinical trials. The company intends to purchase this facility from Inno-Haven, LLC.
- Orphan Drug Designation: The anti-Dengue drug candidate (DengueCide) received Orphan Drug Designation from both the US FDA and the European Medicines Agency (EMA), offering potential tax credits and a Priority Review Voucher.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management believes the company has sufficient cash on hand (approximately $36.7M at year-end, plus subsequent financing) to fund operations for more than 24 months. The primary focus is advancing Injectable FluCide (for hospitalized patients) toward an Investigational New Drug (IND) application and initial human clinical trials. The company also plans to advance Oral FluCide and DengueCide. Management estimates an additional $10M to $15M will be required over the next 36-48 months for human clinical development of these candidates.
Subsequent Events: Following the fiscal year end, the company accepted a $5M Series C Convertible Debenture and warrant exercises totaling ~$7.5M, bringing estimated cash on hand to approximately $48.6M as of mid-September 2014.
Risks and Contingencies
- Development Stage: The company has no approved products, no revenue, and a history of significant losses. There is no assurance that any drug candidates will be approved or become profitable.
- Capital Requirements: The company will need to raise substantial additional capital to complete clinical trials and commercialization. Failure to secure funding could force operational reductions.
- Regulatory Approval: All drug candidates are in pre-clinical stages. Success depends on obtaining FDA approval, which is uncertain, time-consuming, and expensive.
- Third-Party Dependence: The company relies on TheraCour Pharma, Inc. for the core technology and manufacturing of nanomaterials, and on third-party contractors for clinical testing.
- Legal Proceedings: A shareholder derivative lawsuit (Yidam, Ltd.) was settled in September 2014 with the company agreeing to reimburse the plaintiff $150,000 for legal fees.
Investor Verification Checklist
- Cash Runway: Verify the exact cash balance and burn rate to confirm the "24+ months" runway claim, considering the $6M budgeted for the facility purchase.
- Facility Transaction: Confirm the final purchase price and terms for the Shelton, CT facility from Inno-Haven, LLC, and the status of the related related-party transaction disclosures.
- IND Timeline: Assess the realistic timeline for filing the IND for Injectable FluCide, noting the dependency on completing "Tox Package" studies and facility validation.
- TheraCour Relationship: Review the terms of the exclusive license agreement with TheraCour Pharma, Inc., including royalty obligations (15% of net sales) and development fees.
- Subsequent Financing: Confirm the details of the $5M debenture issued to Dr. Milton Boniuk and the $7.5M in warrant exercises to understand the current capital structure.